The short version of Stenabolic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-10 and is reviewed periodically as new material appears.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Flame fuel thickening compounds == Many fuels used in incendiary devices require thickening for increased performance. Aluminium salts of fatty acids are frequently used. Some formulations (e.g. Napalm-B) use polymeric thickeners. Thickened pyrophoric agent, a pyrophoric replacement of napalm, is a triethylaluminium thickened with polyisobutylene. Fuel thickeners are mostly composed of the same thickeners as polar liquids (water), due to the fact that they are amphiphile, that is, they have a polar and an apolar group. The only change is in the orientation of these groups. In the non-polar medium reverse micelle formation occurs. Because the hydrocarbon-hydrocarbon type intermolecular interactions are the weakest, the reverse micelle is much more unstable than the normal micelle. The main gelled fuel precursors are commonly derived from weak acids and strong or weak bases.
== Function == This gene encodes the alpha chain of type XVI collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Members of this collagen family are found in association with fibril-forming collagens such as type I and II, and serve to maintain the integrity of the extracellular matrix. High levels of type XVI collagen have been found in fibroblasts and keratinocytes, and in smooth muscle and amnion.
Sulfur polycations, S82+, S42+ and S192+ are produced when sulfur is reacted with oxidising agents in a strongly acidic solution. The colored solutions produced by dissolving sulfur in oleum were first reported as early as 1804 by C.F. Bucholz, but the cause of the color and the structure of the polycations involved was only determined in the late 1960s. S82+ is deep blue, S42+ is yellow and S192+ is red. Reduction of sulfur gives various polysulfides with the formula Sx2-, many of which have been obtained in crystalline form. Illustrative is the production of sodium tetrasulfide:
For example, Gioja (current Gioia Tauro), was fortified with city walls reinforced by watchtowers to defend against incursions. Several Calabrian cities such as Palmi (where the Saracen Tower stands) and Reggio Calabria were fortified with towers. Despite the heavy taxation and the growth of baronial power, the population remained loyal to the sovereign, seen as a defender of the poor people against the abuses of the powerful. In 1647–1648, exasperated by the excessive tax burden, people in Catanzaro stormed the offices of the tax collectors (arrendatori). The governor intervened and had the leaders of the revolt hanged, causing the rest to flee.
Sources: en.wikipedia.org
Diallyl disulfide (DADS or 4,5-dithia-1,7-octadiene) is an organosulfur compound derived from garlic and a few other plants in the genus Allium. Along with diallyl trisulfide and diallyl tetrasulfide, it is one of the principal components of the distilled oil of garlic. It is a yellowish liquid which is insoluble in water and has a strong garlic odor. It is produced during the decomposition of allicin, which is released upon crushing garlic and other plants of the family Alliaceae. Diallyl disulfide has many of the health benefits of garlic, but it is also an allergen causing garlic allergy. Highly diluted, it is used as a flavoring in food. It decomposes in the human body into other compounds such as allyl methyl sulfide.
Linus Pauling Online a Pauling portal created by Oregon State University Libraries Crick, Francis, "The Impact of Linus Pauling on Molecular Biology" (transcribed from video at the 1995 Oregon State University symposium) The Ava Helen and Linus Pauling Papers at the Oregon State University Libraries The Pauling Catalogue Center for Oral History. "Linus C. Pauling". Science History Institute. Sturchio, Jeffrey L. (1987-04-06). Linus C. Pauling, Transcript of an Interview Conducted by Jeffrey L. Sturchio in Denver, Colorado on 6 April 1987 (PDF). Philadelphia, PA: Chemical Heritage Foundation. The Pauling Blog Linus Pauling (1901–1994) Berkeley Conversations With History interview Linus Pauling Centenary Exhibit Linus Pauling from The Dictionary of Unitarian and Universalist Biography Archived October 16, 2018, at the Wayback Machine "It's in the Blood! A Documentary History of Linus Pauling, Hemoglobin and Sickle Cell Anemia – Special Collections & Archives Research Center – Oregon State University". Oregon State University Library. Retrieved 2015-02-25. The Linus Pauling Institute at Oregon State University Publications of Pauling The Linus Pauling Papers – Profiles in Science, National Library of Medicine Linus Pauling Archived July 19, 2019, at the Wayback Machine Documentary produced by Oregon Public Broadcasting Oral history interview with Linus C. Pauling from Science History Institute Digital Collections
== Government investment and oversight == Between 2020 and 2024, the Ugandan government invested approximately UGX 723.4 billion in Dei BioPharma through multiple budget allocations. The investment sparked parliamentary scrutiny, with the Leader of the Opposition, Joel Ssenyonyi, questioning the absence of key documents such as a valuation by the Chief Government Valuer and a formal memorandum of understanding. The Auditor General’s report further raised concerns about the lack of share certificates and valuation documentation. In response to mounting questions, the company indicated a willingness to refund the investment, although no formal agreement had been reached as of late 2024.
=== Biosciences === Culture tubes are test tubes used in biology and related sciences for handling and culturing all kinds of live organisms, such as molds, bacteria, seedlings, plant cuttings, etc.. Some racks for culture tubes are designed to hold the tubes in a nearly horizontal position, so as to maximize the surface of the culture medium inside. Culture tubes for biology are usually made of clear plastic (such as polystyrene or polypropylene) by injection molding and are often discarded after use. Plastic test tubes with a screwtop cap are often called "Falcon tubes" after a line manufactured by Becton Dickinson. Some sources consider that the presence of a lip is what distinguishes a test tube from a culture tube.
Bagwell set the record for the fewest plate appearances in a season reaching 100 of both runs scored and runs driven in and became the first National Leaguer to finish first or second in batting average, home runs, RBI, and runs scored since Willie Mays in 1955. His .750 SLG at the time ranked as the seventh-best ever and was the highest by a National Leaguer since Rogers Hornsby in 1925 (.756). Further, at the time in National League history, the 213 OPS+ trailed only Hornsby's 1924 season (222 OPS+) for the second-highest ever. The 116 RBI in 110 games qualified for the 13th-highest ratio in history. He also hit 23 home runs in 56 games at the Astrodome, setting a record that stood for the stadium that was famed to be pitcher-friendly until the Astros moved out following the 1999 season. He set single-season club records for batting average, SLG, OPS, OPS+, AB/HR, and offensive win percentage (.858), as well as home runs, breaking Wynn's 27-year-old record, and RBI, breaking Bob Watson's record 17 years earlier. Bagwell broke the team home run and RBI records later in his career. The unanimous winner of the NL Most Valuable Player Award, he became the fourth player in National League history to win by this distinction, and the first Astros player to win the award. Bagwell also won his first Silver Slugger, Gold Glove, and Player of the Year Awards from The Sporting News, Associated Press, Baseball Digest, and USA Today Baseball Weekly. "Crazy stuff happened that year", Bagwell recalled of his 1994 season. "Every pitch that I was looking for, I got.
Sources: en.wikipedia.org
== Contributions to Pharmaceutical Chemistry == DeGrado contributed significantly to the development of Brilacidin, which is in clinical trials for several indications. DeGrado's group also has contributed to the development of small molecule antagonists of integrins that reached clinical trials. His work on this subject with Dean Sheppard also formed the basis for founding Pliant Pharmaceuticals, a company conducting clinical trials on idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis.
== Natural and synthetic cannabinoids == The following are banned for in-competition use only, with the exception of cannabidiol (CBD) which is not banned for any use. In 2013, the level of THC metabolite allowed was changed from 15 ng/mL to 150 ng/mL so as to only detect in-competition use.
=== Symmetrical flow === Of these techniques flow FFF was the first to be offered commercially. Flow FFF separates particles based on size, independent of density and can measure macromolecules in the range of 1 nm to 1 μm. In this respect it is the most versatile FFF sub-technique available. The cross flow in Flow FFF enters through a porous frit at the top of the channel, exiting through a semi-permeable membrane outlet frit on the accumulation wall (i.e. the bottom wall). Symmetrical flow has been replaced by asymmetrical flow in the last two decades.
== Biography == Born in Mwan in 1902, Mailo was educated at the Protestant Mission School at Anopouou. After leaving school in 1914, he worked on a trading boat between 1915 and 1920. The Japanese authorities appointed Mailo to the post of secretary of Moen island in 1932. The following year, he succeeded his uncle as Chief of Nepukos village. In 1936 he became Leader of Section No. 2 of Moen island, holding the role until 1938. Between 1939 and 1944 he was employed by the Japanese government as an advisor on native affairs. In 1947 he became Chief of Moen, succeeding his brother Albert. In 1957 the position was reconstituted as a mayoral post and made elective, with Mailo elected to the post. In the same year, he was elected to Truk Congress, serving as president of the legislature in 1957 and 1958. He also became president of the Truk Trading Company. In 1965 Mailo was elected to the General Assembly of the new Congress of the Trust Territory of the Pacific Islands as the Moen representative. The body was later renamed the House of Representatives and Mailo was re-elected in 1966, remaining in office until the 1968 elections. He subsequently served on the board of Air Micronesia. He died in Truk Hospital in September 1971 at the age of 68, survived by wife Chimako and eleven children.
Under traditional terminology, the American kestrel is the smallest raptor in the Americas, though the South American spot-winged falconet is almost as small. The American kestrel is sexually dimorphic, although there is some overlap in plumage coloration between the sexes. The bird ranges from 22 to 31 cm (8.7 to 12.2 in) in length with a wingspan of 51–61 cm (20–24 in). The female kestrel is larger than the male, though less so than larger falcons, being typically about 10% to 15% larger within a subspecies. The more northern subspecies tend to larger sizes (northern hemisphere), with a large northern female being about twice the size of a small southern male. The male typically weighs 80–143 g (2.8–5.0 oz), and the female 86–165 g (3.0–5.8 oz). In standard measurements, the wing bone is 16–21 cm (6.3–8.3 in) long, the tail is 11–15 cm (4.3–5.9 in) and the tarsus is 3.2–4 cm (1.3–1.6 in). Physically, American kestrels are leaner and less muscular than larger falcons. The pectoral flight muscles of the American kestrel make up only about 12% of its body weight, as compared to about 20% for the strongest flying falcons such as the peregrine falcon. The wings are moderately long, fairly narrow, and taper to a point. Their less muscular body type is adapted to energy-conserving ambush hunting, rather than spending large amounts of energy-consuming time on the wing and getting into long tail-chases of bird prey. For their size, they have strong talons and beaks, and can swiftly dispatch prey.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.